Drug Trial Radar · NCT06967610
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Jun 1, 2031
Study completion Jun 1, 2033
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eli Lilly and Company
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia (SLL)
Interventions
PirtobrutinibDrug
Given PO 200mg daily
VenetoclaxDrug
Given PO daily
ObinutuzumabDrug
Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse eventsTime frame: Through study completion; an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.